EGFR and non-small cell lung carcinoma: Collectively, these results demonstrated an inhibitory effect of the CMTM6‐targeting nanobody 1A5 on the growth of TKI‐resistant NSCLC tumors, supporting the therapeutic potential of 1A5 in NSCLC intervention to overcome the resistance to EGFR TKIs.